Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Landon L Chan

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Clinical Lung Cancer|February 11, 2025
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib ProgressionWesley K Y Wong, Kevin K S Mok, Giselle P C Tsui, et al.
Lung Cancer (Amsterdam, Netherlands)|November 4, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinibAllen C C Chen, Florence S T Mok, Wesley K Y Wong, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
Radiation-induced lymphopenia is associated with survival in patients with hepatocellular carcinoma treated with stereotactic body radiotherapyLandon L Chan, Vanessa T Y Yeung, Winnie M T Soo, et al.
JTO Clinical and Research Reports|April 9, 2024
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung DiseaseMolly S C Li, Kirsty W C Lee, Kevin K S Mok, et al.
Cell Genomics|February 7, 2026
Holistic determination of ends of cfDNA moleculesPeiyong Jiang, Mary-Jane L Ma, Rong Qiao, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2024
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLCStephanie P L Saw, Yi Fen Low, Gillianne G Y Lai, et al.
Med (New York, N.Y.)|April 10, 2025
Chromatin accessibility states affect transrenal clearance of plasma DNA: Implications for urine-based diagnosticsMary-Jane L Ma, Woody Z Zhang, Peiyong Jiang, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Clinical Lung Cancer|February 11, 2025
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib ProgressionWesley K Y Wong, Kevin K S Mok, Giselle P C Tsui, et al.
Lung Cancer (Amsterdam, Netherlands)|November 4, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinibAllen C C Chen, Florence S T Mok, Wesley K Y Wong, et al.
JHEP Reports : Innovation in Hepatology|April 8, 2026
Radiation-induced lymphopenia is associated with survival in patients with hepatocellular carcinoma treated with stereotactic body radiotherapyLandon L Chan, Vanessa T Y Yeung, Winnie M T Soo, et al.
JTO Clinical and Research Reports|April 9, 2024
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung DiseaseMolly S C Li, Kirsty W C Lee, Kevin K S Mok, et al.
Cell Genomics|February 7, 2026
Holistic determination of ends of cfDNA moleculesPeiyong Jiang, Mary-Jane L Ma, Rong Qiao, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2024
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLCStephanie P L Saw, Yi Fen Low, Gillianne G Y Lai, et al.
Med (New York, N.Y.)|April 10, 2025
Chromatin accessibility states affect transrenal clearance of plasma DNA: Implications for urine-based diagnosticsMary-Jane L Ma, Woody Z Zhang, Peiyong Jiang, et al.
Human Molecular Genetics|September 1, 2012
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variantsBrian D Juran, Gideon M Hirschfield, Pietro Invernizzi, et al.
Pageof 3